Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
View original at finance.yahoo.com“Rani no longer has any outstanding debt obligations as of December 31, 2025.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Throughout 2025, we generated a robust body of preclinical evidence for RT-114 and our oral semaglutide, demonstrating the potential of the RaniPill platform to enable oral delivery of complex incretin-based therapies
60% confidenceWe entered 2026 at an important inflection point, highlighted by the initiation of our Phase 1 study of RT-114, our first orally administered GLP-1/GLP-2 (PG-102) dual agonist delivered via the RaniPill capsule
60% confidenceWith the initiation of our Phase 1 trial of RT-114 in December 2025, we are well positioned to advance our first oral GLP-1/GLP-2 dual agonist into clinical development and continue unlocking the potential of the RaniPill platform across high-value therapeutic areas
60% confidenceRT-116 was well tolerated with no serious adverse events
60% confidenceThe partnership demonstrates RaniPill's potential to convert injectable biologics into oral therapies, improving patient adherence and accessibility
60% confidence
